Potent dynamin I and II inhibitor. Inhibits dynamin I GTPase (IC50 = 2.3 μM) and targets pleckstrin homology (PH) (lipid binding) domain. Inhibits receptor-mediated and synaptic vesicle endocytosis (IC50 values are 9.3 and 7.1 μM, respectively).
Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. RTIL™ is a trademark of Children's Medical Research Institute and Newcastle Innovation Ltd.
Store at Room Temperature. Store under desiccating conditions. The product can be stored for up to 12 months.
Soluble in DMSO to 20 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
Functional Studies - RTIL-13™ (ab120465)
ab13847 staining active caspase 3 in HeLa cells treated with RTIL-13™ (ab120465), by ICC/IF. Increase in active caspase 3 expression correlates with increased concentration of RTIL-13™, as described in literature. The cells were incubated at 37°C for 24h in media containing different concentrations of ab120465 (RTIL-13™) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab13847 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.